×
IQVIA has launched the AI Orchestrator agent, powered by IQVIA Connected Intelligence and NVIDIA AI Foundry, to enhance the efficiency of clinical trials and pharmaceutical commercialization processes, enabling new therapies to reach patients more quickly.
Despite global annual investments in drug development amounting to tens of billions of euros, the number of new drugs that ultimately reach the market remains limited.
Agentic AI is driving transformative breakthroughs in the pharmaceutical industry. IQVIA, a global leader in providing clinical research services, commercial analytics, and healthcare intelligence, plays a pivotal role in this evolution.
During NVIDIA GTC Paris at VivaTech, IQVIA announced a collaboration with NVIDIA to launch multiple AI Orchestrator agents. These agent systems are designed to support IQVIA’s thousands of pharmaceutical, biotech, and medical device clients worldwide, accelerating their complex drug development workflows.
The AI Orchestrator agent acts like a “conductor” in an orchestra, with specialized sub-agents handling distinct tasks—analogous to string, woodwind, bass, and percussion sections. The Orchestrator intelligently assigns necessary tasks (e.g., speech-to-text conversion, clinical term coding, structured data extraction, and content summarization) to the appropriate sub-agents, ensuring efficient execution of each step under human experts’ oversight.
Leveraging its vast databases and deep healthcare domain expertise, IQVIA can train and fine-tune AI models for specific tasks, driving greater productivity and efficiency.
Agentic AI Accelerates Clinical Trial Progress
IQVIA’s expertise in navigating regulatory compliance requirements across countries—including multiple European nations—positions it as a key player in clinical research.
The newly launched AI Orchestrator agents are deployed on its medical-grade AI platform, enabling acceleration across the entire drug development lifecycle, including clinical trial phases.
For pharmaceutical companies, clinical trials represent a critical milestone in drug development, yet their planning and execution often span years. The startup phase alone typically takes around 200 days and relies heavily on manual processes.
IQVIA’s AI Orchestrator agent for clinical trial startup is specifically designed to address the urgent need for accelerated trial initiation.
A key area where the IQVIA AI Orchestrator agent drives acceleration is target identification. By building knowledge graphs from research literature and biomedical databases, combined with customized AI models, the agent extracts key relationships and generates insights. This knowledge helps IQVIA’s pharmaceutical clients identify emerging scientific areas, prioritize indications (e.g., determining which indications to explore—and in what order—for a specific drug asset), uncover new repurposing opportunities, and unlock previously untapped uses.
Meanwhile, the clinical data review agent can detect data issues early through a series of automated checks and specialized sub-agents, shortening the data review process from seven weeks to as little as two.
Avinob Roy, Vice President and General Manager of IQVIA’s Commercial Analytics Solutions Product Supply, stated: “From molecular discovery to market access, AI holds the potential to revolutionize the life sciences and healthcare sector.”
IQVIA’s agents leverage NVIDIA NIM microservices from the NVIDIA AI Enterprise software platform to streamline clinical site startup processes. The agents guide sub-agents in analyzing clinical trial protocols, extracting key patient inclusion and exclusion criteria, and resolving issues through phased reasoning. By deploying autonomous Orchestrator agents, research teams can focus on decision-making rather than time-consuming administrative tasks.
AI Agents Chart New Paths for Pharmaceutical Commercialization
After a drug clears clinical trials, significant work remains before it reaches patients.
Pharmaceutical companies must understand the market landscape, the state of the disease area, map patient journeys, and plan treatment pathways—all to identify the right patient populations and find effective ways to reach them.
Roy noted, “Truly understanding these challenges requires integrating diverse factors like market dynamics, patient behavior, accessibility hurdles, and competitive landscapes.”
The IQVIA Orchestrator agent can analyze patient records, prescriptions, and lab results to comprehensively map how a treatment reaches patients—not in weeks, but in days.
Another challenge is capturing healthcare professionals’ attention. To stand out among competing treatments, field teams engaging with healthcare providers often spend hours preparing for each interaction, crafting data-driven, personalized communications that deliver real value.
IQVIA’s Field Partner Orchestrator agent provides tailored insights to pharmaceutical sales teams before each interaction with healthcare providers. By integrating physicians’ background profiles, digital behaviors, prescribing patterns, and real-time patient dynamics, the agent leverages near-live analytics to help field teams prepare for meetings and drive more impactful discussions.
Roy stated, “The synergy of these agents across commercial workflows brings unprecedented precision and operational efficiency to the life sciences, tangibly improving experiences and outcomes for healthcare professionals and patients alike.”
Follow NVIDIA GTC Paris at VivaTech to learn about AI breakthroughs in healthcare and beyond.
Watch NVIDIA Founder and CEO Jensen Huang’s keynote at NVIDIA GTC Paris during VivaTech 2025 and explore more from GTC Paris.
EN
